UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053035
Receipt number R000060509
Scientific Title A verification study of the anti-ultraviolet light effects of the test food: a randomized, placebo-controlled, double-blind, parallel-group comparison study
Date of disclosure of the study information 2023/12/08
Last modified on 2024/04/19 09:21:38

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A verification study of the anti-ultraviolet light effects of the test food

Acronym

A verification study of the anti-ultraviolet light effects of the test food

Scientific Title

A verification study of the anti-ultraviolet light effects of the test food: a randomized, placebo-controlled, double-blind, parallel-group comparison study

Scientific Title:Acronym

A verification study of the anti-ultraviolet light effects of the test food

Region

Japan


Condition

Condition

Healthy Japanese

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To verify the anti-ultraviolet light effects of the test food consumption.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

1. The measured value of minimum erythema dose (MED) at eight weeks after consumption (8w)

Key secondary outcomes

1. The measured values of skin tone (L*-value, a*-value, b*-value), transepidermal water loss, skin moisture content, and viscoelasticity of skin at 8w

2. The measured value of original questionnaire at 8w


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation


Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Duration: Eight weeks
Test food: Active food 1

Interventions/Control_2

Duration: Eight weeks
Test food: Placebo food

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Japanese

2. Men or women

3. Adults

4. Healthy individuals

5. Individuals who have skin type II or III on the Fitzpatrick Scale

6. Individuals who have relatively low MED at screening (before consumption) among those who met the inclusion criteria No. 1~5

Key exclusion criteria

Individuals (who)
1. are undergoing treatment or have a history of malignant tumor (including skin cancer), heart failure, myocardial infarction, or atopic dermatitis
2. have a pacemaker or an implantable cardioverter defibrillator
3. under treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. take "Foods for Specified Health Uses" or "Foods with Functional Claims"
5. take medications, herbal medicines, or supplements
6. are allergic to medicines, the test food related products, and/or crustaceans
7. engage in occupations involving outdoor work
8. plan outings or other activities, such as swimming in the sea, mountain climbing, or winter sports, involving a lot of sunlight during the study
9. use or practice daily skincare (e.g., body scrub, strigilation) except for cosmetic creams, beauty essence, all-in-one cosmetic makeup, skin lotions, face masks, milky lotions, and sunscreen
10. habitually receive skincare treatment (e.g., aesthetic treatment, massage) or use instruments for beauty treatment (e.g., facial treatment device)
11. have skin which always reddens and never darkens after sun exposure or tanning salon treatment, or have been pointed out by a third party for that
12. have developed urticaria after sun exposure or tanning salon treatment, or have been pointed out by a third party for that
13. are exposed to ultraviolet light (UV) daily (e.g., arc welding and fusing work, work under UV sterilization light, genetic testing work)
14. with art makeup or tattoos
15. are pregnant, lactating, or planning to become pregnant during the study
16. have been enrolled in other clinical studies within the last 28 days before the agreement to participate or plan to participate another study during the study
17. are judged as ineligible to participate in the study by the physician

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Tatsuya
Middle name
Last name Izumi

Organization

Hiroo Dermatology Clinic & Mentors inc.

Division name

Director

Zip code

150-0012

Address

1&2F Hiroo Masugi Annex Bldg., 5-25-5, Hiroo, Shibuya-ku, Tokyo, Japan

TEL

03-5795-1112

Email

dr_izumi@orthomedico.jp


Public contact

Name of contact person

1st name Naoko
Middle name
Last name Suzuki

Organization

ORTHOMEDICO Inc.

Division name

R&D Department

Zip code

112-0002

Address

2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan

TEL

03-3818-0610

Homepage URL


Email

nao@orthomedico.jp


Sponsor or person

Institute

ORTHOMEDICO Inc.

Institute

Department

Personal name



Funding Source

Organization

BGG Japan Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Hiroo Dermatology Clinic & Mentors inc.

Medical Corporation Seishinkai, Takara Clinic

Nerima Medical Association, Minami-machi Clinic

Name of secondary funder(s)



IRB Contact (For public release)

Organization

The ethical committee of the Takara Clinic, Medical Corporation Seishinkai

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

Tel

03-5793-3623

Email

IRB@takara-clinic.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

広尾皮フ科クリニック (東京都)
Hiroo Dermatology Clinic & Mentors inc. (Tokyo, Japan)

医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)

南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)


Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 08 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

44

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2023 Year 10 Month 25 Day

Date of IRB

2023 Year 10 Month 25 Day

Anticipated trial start date

2023 Year 12 Month 08 Day

Last follow-up date

2024 Year 06 Month 10 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 12 Month 08 Day

Last modified on

2024 Year 04 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060509


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name